CPCeleste Leigh Pearce

Celeste Leigh Pearce

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Celeste Leigh Pearce has a total of 248 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk

    by Rikki Cannioto, Michael J. LaMonte, Harvey A. Risch, Chi-Chen Hong, Lara E. Sucheston-Campbell, Kevin H. Eng, J. Brian Szender, Jenny Chang-Claude, Barbara Schmalfeldt, Ruediger Klapdor, et al.

    (Abstracted from Cancer Epidemiol Biomarkers Prev 2016;25(7):1114–1124) It is estimated that 5% of women in the United States and 10% to 50% of women worldwide are physically inactive. Previous studies have demonstrated that recreational physical activity is associated with decreased risks of developing breast, colon, and endometrial cancers.

  • Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk

    by Alice W. Lee, Roberta B. Ness, Lynda D. Roman, Kathryn L. Terry, Joellen M. Schildkraut, Jenny Chang-Claude, Jennifer A. Doherty, Usha Menon, Daniel W. Cramer, Simon A. Gayther, et al.


  • Expression of Wnt-Signaling Pathway Genes and Wnt-Target Genes in Human Endometriosis Tissue [25]

    by Doerthe Brueggmann, Jenny M. Jaque, Celeste Leigh Pearce, Claire Templeman


  • Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer

    by Celeste Leigh Pearce, Mary Anne Rossing, Alice W. Lee, Roberta B. Ness, Penelope M. Webb, for Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group, Georgia Chenevix-Trench, Susan M. Jordan, Douglas A. Stram, et al.

    Background: There are several well-established environmental risk factors for ovarian cancer, and recent genome-wide association studies have also identified six variants that influence disease risk. However, the interplay between such risk factors and susceptibility loci has not been studied. Methods: Data from 14 ovarian cancer case–control studies were pooled, and stratified analyses by each environmental risk factor with tests for heterogeneity were conducted to determine the presence of interactions for all histologic subtypes. A genetic “risk score” was created to consider the effects of all six variants simultaneously. A multivariate model was fit to examine the association between all environmental risk factors and genetic risk score on ovarian cancer risk. Results: Among 7,374 controls and 5,566 cases, there was no statistical evidence of interaction between the six SNPs or genetic risk score and the environmental risk factors on ovarian cancer risk. In a main effects model, women in the highest genetic risk score quartile had a 65% increased risk of ovarian cancer compared with women in the lowest [95% confidence interval (CI), 1.48–1.84]. Analyses by histologic subtype yielded risk differences across subtype for endometriosis (Phet < 0.001), parity (Phet < 0.01), and tubal ligation (Phet = 0.041). Conclusions: The lack of interactions suggests that a multiplicative model is the best fit for these data. Under such a model, we provide a robust estimate of the effect of each risk factor that sets the stage for absolute risk prediction modeling that considers both environmental and genetic risk factors. Further research into the observed differences in risk across histologic subtype is warranted. Cancer Epidemiol Biomarkers Prev; 22(5); 880–90. ©2013 AACR.


  • Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine

    by Melissa A. Frasco, Wendy J. Mack, David Van Den Berg, Bradley E. Aouizerat, Kathryn Anastos, Mardge Cohen, Jack De Hovitz, Elizabeth T. Golub, Ruth M. Greenblatt, Chenglong Liu, et al.

    Objective: CYP2B6 variation predicts pharmacokinetic characteristics of its substrates. Consideration for underlying genetic structure is critical to protect against spurious associations with the highly polymorphic CYP2B6 gene. Design: The effect of CYP2B6 variation on response to its substrates, nonnucleoside reverse transcriptase inhibitors (NNRTIs), was explored in the Women's Interagency HIV Study. Methods: Five putative functional polymorphisms were tested for associations with virologic suppression within 1 year after NNRTI initiation in women naive to antiretroviral agents (n = 91). Principal components were generated to control for population substructure. Logistic regression was used to test the joint effect of rs3745274 and rs28399499, which together indicate slow, intermediate, and extensive metabolizers. Results: Rs3745274 was significantly associated with virologic suppression [odds ratio = 3.61, 95% confidence interval (CI) 1.16–11.22, P trend = 0.03]; the remaining polymorphisms tested were not significantly associated with response. Women classified as intermediate and slow metabolizers were 2.90 (95% CI 0.79–12.28) and 13.44 (95% CI 1.66 to infinity) times as likely to achieve virologic suppression compared to extensive metabolizers after adjustment for principal components (P trend = 0.005). Failure to control for genetic ancestry resulted in substantial confounding of the relationship between the metabolizer phenotype and treatment response. Conclusion: The CYP2B6 metabolizer phenotype was significantly associated with virologic response to NNRTIs; this relationship would have been masked by simple adjustment for self-reported ethnicity. Given the appreciable genetic heterogeneity that exists within self-reported ethnicity, these results exemplify the importance of characterizing underlying genetic structure in pharmacogenetic studies. Further follow-up of the CYP2B6 metabolizer phenotype is warranted, given the potential clinical importance of this finding.


  • Top Cited Papers
    Open Access

    Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies

    by Celeste Leigh Pearce, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M Near, Penelope M Webb, Christina M Nagle, Jennifer A Doherty, Kara L Cushing-Haugen, Kristine G Wicklund, et al.


  • Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk

    by Celeste Leigh Pearce, Jennifer A. Doherty, David J. Van Den Berg, Kirsten Moysich, Chris Hsu, Kara L. Cushing-Haugen, David V. Conti, Susan J. Ramus, Aleksandra Gentry-Maharaj, Usha Menon, et al.

    The insulin-like growth factor (IGF) signaling axis plays an important role in cancer biology. We hypothesized that genetic variation in this pathway may influence risk of ovarian cancer. A three-center study of non-Hispanic whites including 1880 control women, 1135 women with invasive epithelial ovarian cancer and 321 women with borderline epithelial ovarian tumors was carried out to test the association between tag single-nucleotide polymorphisms (tSNPs) (n=58) in this pathway and risk of ovarian cancer. We found no association between variation in IGF1, IGFBP1 or IGFBP3 and risk of invasive disease, whereas five tSNPs in IGF2 were associated with risk of invasive epithelial ovarian cancer at P<0.05 and followed-up one of the associated SNPs. We conducted genotyping in 3216 additional non-Hispanic white cases and 5382 additional controls and were able to independently replicate our initial findings. In the combined set of studies, rs4320932 was associated with a 13% decreased risk of ovarian cancer per copy of the minor allele carried (95% confidence interval 0.81-0.93, P-trend=7.4 × 10(-5)). No heterogeneity of effect across study centers was observed (p(het)=0.25). IGF2 is emerging as an important gene for ovarian cancer; additional genotyping is warranted to further confirm these associations with IGF2 and to narrow down the region harboring the causal SNP.


  • Open Access

    The Search for Host Genetic Factors of HIV/AIDS Pathogenesis in the Post-Genome Era: Progress to Date and New Avenues for Discovery

    by Bradley E. Aouizerat, C. Leigh Pearce, Christine Miaskowski

    Though pursuit of host genetic factors that influence the pathogenesis of HIV began over two decades ago, progress has been slow. Initial genome-level searches for variations associated with HIV-related traits have yielded interesting candidates, but less in the way of novel pathways to be exploited for therapeutic targets. More recent genome-wide association studies (GWAS) that include different phenotypes, novel designs, and that have examined different population characteristics suggest novel targets and affirm the utility of additional searches. Recent findings from these GWAS are reviewed, new directions for research are identified, and the promise of systems biology to yield novel insights is discussed.


  • Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort

    by Aimee M. Near, Anna H. Wu, Claire Templeman, David J. Van Den Berg, Jennifer A. Doherty, Mary Anne Rossing, Ellen L. Goode, Julie M. Cunningham, Robert A. Vierkant, Brooke L. Fridley, et al.


  • Open Access

    Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin

    by Celeste Leigh Pearce, Karine Chung, Malcolm C. Pike, Anna H. Wu

    BACKGROUND.: It has become increasingly clear that use of menopausal hormone therapy (HT) is associated with an increased risk of ovarian cancer; however, the effects by type of formulation and duration of use are less clear. A systematic review of the HT and ovarian cancer literature was conducted to identify population‐based case‐control studies, cohort studies, and randomized trials that examined effects by formulation of HT (estrogen‐alone [ET] and estrogen plus progestin [EPT]) and duration of use.METHODS.: Pub‐Med (www.pubmed.gov) was used to identify relevant publications through December 2007; 14 studies were identified. The authors abstracted relative risks (RRs) and 95% confidence intervals (CIs) in relation to duration of HT use (ET and EPT separately). The authors used the risk estimates per year of HT use if these were provided; otherwise, they calculated a duration‐response for a log‐linear model of the duration of HT use against risk.RESULTS.: Ovarian cancer risk was increased among ET users (RR per 5 years of use, RR5 = 1.22; 95% CI, 1.18‐1.27; P < .0001), and a lower but still statistically significant increased risk was seen with EPT use (RR5 = 1.10; 95% CI, 1.04‐1.16; P = .001). The increased risk in ET users was statistically significantly higher than the increased risk in EPT users (P = .004).CONCLUSIONS.: ET use increases risk of ovarian cancer in a duration‐dependent manner, and it appears that the addition of progestins blocks this effect, at least to some extent. Whether the effect of estrogens would be completely blocked if progestins were given every day is unclear. Cancer 2009. © 2009 American Cancer Society.